Latest Astellas Pharma Inc. Stories

2011-08-09 07:00:00

SAN MATEO, Calif., Aug. 9, 2011 /PRNewswire/ -- Recent Highlights: Completed equity and debt financing totaling $40 million Qutenza® (capsaicin) 8% patch launch in U.S. building momentum in large U.S. institutions; 432 institutions purchased as of 2Q11, up 34% from 1Q11 Sales of Qutenza to end user customers increased 23% over 1Q11 2Q11 revenue totaled $2.5 million including $0.5 million U.S. Qutenza product revenue EU launch by Astellas advancing, with Qutenza...

2011-06-13 07:30:00

LONDON, June 13, 2011 /PRNewswire/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor. The study is evaluating AC220 as an oral, once-a-day, monotherapy treatment in acute myeloid leukemia (AML) in 240 patients with FLT3-ITD activating mutations who have relapsed or are refractory to other treatments, including chemotherapy and...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.